ENANTA PHARMACEUTICALS Business Summary

Enanta Pharmaceuticals Inc. (ENTA) is a clinical-stage biotechnology company that generates revenue primarily through a royalty-based business model, anchored by its long-standing collaboration with AbbVie for the hepatitis C virus (HCV) treatment MAVYRET/MAVIRET. The company’s primary business segments are divided into Virology, focusing on respiratory syncytial virus (RSV), hepatitis B virus (HBV), and SARS-CoV-2, and Immunology, where it develops oral small-molecule inhibitors for type 2 inflammatory diseases like atopic dermatitis and asthma. Enanta monetizes its future cash flows through strategic royalty sales, such as its agreement with OMERS, to fund its internal R&D pipeline and maintain a multi-year cash runway. Direct competitors include Vir Biotechnology, Arrowhead Pharmaceuticals, and Alnylam Pharmaceuticals; Enanta distinguishes itself in this landscape as a chemistry-focused specialist leveraging established commercial royalties to advance a proprietary, wholly-owned clinical portfolio. Founded in 1995, Enanta is led by President and CEO Dr. Jay R. Luly, who joined in 2003 and brings a pedigree from Abbott Laboratories and Millennium Pharmaceuticals. The executive team includes Chief Scientific Officer Dr. Yat Sun Or, a veteran of Abbott who has been with the company since 1999, and Chief Medical Officer Dr. Scott Rottinghaus, formerly of Alexion and AstraZeneca. Due to the ongoing medical leave of Paul J. Mellett, financial leadership is currently managed by Interim Principal Financial Officer Harry R. Trout III and Interim Principal Accounting Officer Kathleen S. Capps. The company’s strategic direction is overseen by a board chaired by Dr. Bruce L.A. Carter, with notable historical backing from institutional investors such as HBM Partners and Omega Funds.